Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes

Antiviral Therapy

Volumn 22, Issue 7, 2017, Pages 577-586

  Bhagwat, Priya ^a,b   Ofotokun, Ighovwerha ^c   McComsey, Grace A ^d   Brown, Todd T ^e   Moser, Carlee ^f   Sugar, Catherine A ^b   Currier, Judith S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RALTEGRAVIR;

ABDOMINAL FAT; ADULT; AGED; ANTIRETROVIRAL THERAPY; ARTICLE; BODY COMPOSITION; BODY MASS; BODY SIZE; CAUCASIAN; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CORRELATIONAL STUDY; COST EFFECTIVENESS ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAPERITONEAL FAT; MAJOR CLINICAL STUDY; MALE; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TRUNK; WAIST CIRCUMFERENCE; WEIGHT CHANGE; ANALYSIS OF VARIANCE; DIAGNOSTIC IMAGING; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INTRA-ABDOMINAL FAT; METABOLISM; MIDDLE AGED; OBESITY; PATHOLOGY; PROCEDURES; SELF REPORT; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADIPOSITY; ADULT; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; FEMALE; HIV INFECTIONS; HUMANS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SELF REPORT; TOMOGRAPHY, X-RAY COMPUTED; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 85035150194     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3148     Document Type: Article

References (42)

1. Cheruvu S, Holloway CJ. Cardiovascular disease in human immunodeficiency virus. Intern Med J 2014; 44:315–324.
2. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118:e29–e35.
3. Esser S, Gelbrich G, Brockmeyer N, et al. Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. Clin Res Cardiol 2013; 102:203–213.
4. Domingo P, Estrada V, López-Aldeguer J, Villaroya F, Martínez E. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev 2012; 14:112–123.
5. Hughes-Austin JM, Larsen BA, Allison MA. Visceral adipose tissue and cardiovascular disease risk. Curr Cardiovasc Risk Rep 2013; 7:95–101.
6. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011; 53:185–196.
7. Martinez E, Gonzalez-Cordon A, Ferrer E, et al. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial. Clin Infect Dis 2015; 60:811–820.
8. Wronska A, Kmiec Z. Structural and biochemical characteristics of various white adipose tissue depots. Acta Physiol (Oxf) 2012; 205:194–208.
9. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012; 126:1301–1313.
10. Katzmarzyk PT, Heymsfield SB, Bouchard C. Clinical utility of visceral adipose tissue for the identification of cardiometabolic risk in white and African American adults. Am J Clin Nutr 2013; 97:480–486.
11. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116:39–48.
12. Guaraldi G, Stentarelli C, Zona S, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010; 208:222–227.
13. Guaraldi G, Zona S, Orlando G, et al. Progression of coronary artery calcium in men affected by human immunodeficiency virus infection. Int J Cardiovasc Imaging 2012; 28:935–941.
14. Lake JE, Wohl D, Scherzer R, et al. Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care 2011; 23:929–938.
15. Scherzer R, Heymsfield SB, Lee D, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 2011; 25:1405–1414.
16. Amato MC, Guarnotta V, Giordano C. Body composition assessment for the definition of cardiometabolic risk. J Endocrinol Invest 2013; 36:537–543.
17. Després JP, Prud’homme D, Pouliot MC, Tremblay A, Bouchard C. Estimation of deep abdominal adipose-tissue accumulation from simple anthropometric measurements in men. Am J Clin Nutr 1991; 54:471–477.
18. Direk K, Cecelja M, Astle W, et al. The relationship between DXA-based and anthropometric measures of visceral fat and morbidity in women. BMC Cardiovasc Disord 2013; 13:25.
19. Rankinen T, Kim SY, Pérusse L, Després JP, Bouchard C. The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis. Int J Obes Relat Metab Disord 1999; 23:801–809.
20. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73:460–468.
21. Tungsiripat M, O’Riordan MA, Storer N, et al. Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat. HIV Clin Trials 2009; 10:314–319.
22. Abrahams Z, Dave JA, Maartens G, Lesosky M, Levitt NS. The development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settings. AIDS Res Ther 2014; 11:26.
23. Belloso WH, Quirós RE, Ivalo SA, et al. Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 32:104–111.
24. Haubrich RH, Riddler SA, DiRienzo G, et al. Clinical associations of extremity fat loss from ACTG 5142: a prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for antiretroviral therapy (ART) of naive, HIV-1 infected subjects. 15th Conference on Retroviruses and Opportunistic Infections. 3–6 February 2008, Boston, MA, USA.
25. Lennox JL, Landovitz RJ, Ribaudo HJ, et al. A Phase III comparative study of the efficacy and tolerability of three non-nucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive HIV-1-infected volunteers: a randomized, controlled trial. Ann Intern Med 2014; 161:461–471.
26. Ofotokun I, Na LH, Landovitz RJ, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis 2015; 60:1842–1851.
27. Stein JH, Brown TT, Ribaudo HJ, et al. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS 2013; 27:929–937.
28. Kelesidis T, Tran TTT, Stein JH, et al. Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis 2015; 61:651–660.
29. Brown TT, Chen Y, Currier JS, et al. Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1 infected individuals. J Acquir Immune Defic Syndr 2013; 63:323–330.
30. McComsey GA, Moser C, Currier J, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis 2016; 62:853–862.
31. CDC. About adult BMI. (Accessed 14 July 2015.) Available from http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/
32. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol 2006; 163:860–869.
33. Wen M, Kowaleski-Jones L. Sex and ethnic differences in validity of self-reported adult height, weight and body mass index. Ethn Dis 2012; 22:72–78.
34. Krul AJ, Daanen HAM, Choi H. Self-reported and measured weight, height and body mass index (BMI) in Italy, the Netherlands and North America. Eur J Public Health 2011; 21:414–419.
35. Falutz J, Rosenthall L, Kotler D, Zona S, Guaraldi G. Surrogate markers of visceral adipose tissue in treated HIV-infected patients: accuracy of waist circumference determination. HIV Med 2014; 15:98–107.
36. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone–releasing factor in patients with HIV. N Engl J Med 2007; 357:2359–2370.
37. Janiszewski PM, Ross R, Despres J-P, et al. Hypertriglyceridemia and waist circumference predict cardiovascular risk among HIV patients: a cross-sectional study. PLoS One 2011; 6:e25032.
38. Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America’s Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Am J Clin Nutr 2007; 85:1197–1202.
39. Mahy M, Autenrieth CS, Stanecki K, Wynd S. Increasing trends in HIV prevalence among people aged 50 years and older: evidence from estimates and survey data. AIDS 2014; 28:S453–S459.
40. Koethe JR, Jenkins CA, Lau B, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses 2016; 32:50–58.
41. Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS Study. AIDS Res Hum Retroviruses 2013; 29:256–265.
42. Moyle GJ, Hardy H, Farajallah A, DeGrosky M, McGrath D. Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naive patients with HIV-1 infection. Clin Drug Investig 2014; 34:287–296.